Ubrogepant
Migraine With Aura
Messoud Ashina, MDSmall moleculePhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 81/ 100
Competitive context
20 Active assets in the Migraine With Aura cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Topiramate Tongji Hospital | Phase 4 | BBB |
Apsolol Norwegian University of Science and Technology | Phase 3 | BB |
DHE Satsuma Pharmaceuticals, Inc. | Phase 3 | BB |
Rimegepant University of South Florida | Phase 4 | BB |
DFN-11 (SUMATRIPTAN INJECTION) University of Aarhus | Phase 3 | BB |
View all 48 →
Same molecule, other indications
Ubrogepant is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →